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OBJECTIVES: To evaluate changes in health-related quality of
life (HRQoL). METHODS: The OSSO study is a 12-month,
European, prospective, observational study of postmenopausal
women with osteoporosis and an inadequate response to anti-
osteoporosis therapy, deﬁned as: 1) presence of a new fragility
fracture despite prescription of any approved anti-osteoporosis
therapy for at least 12 months before the fracture, and/or 2) dis-
continuation of any approved anti- osteoporosis therapy due to
compliance problems and/or side effects. RESULTS: A total of
418 women enrolled in France were included in the baseline
analysis: 196 (46.90%) had a new fragility fracture and 222
(53.10%) had compliance problems/ side effects, a less severe
patient group based upon baseline patients’ characteristics.
HRQoL was assessed using the osteoporosis disease-speciﬁc
QUALEFFO questionnaire. At baseline, the mean (SD) total
QUALEFFO score for the OSSO French population (n = 418)
was 42.7 (18.8), and the mean (SD) scores for the ﬁve domains
were: pain 46.2 (27.4), physical function 33.0 (23.0), social func-
tion 56.9 (25.9), general health 62.7 (20.7) and mental function
42.4 (19.2). The mean total QUALEFFO score was signiﬁcantly
higher in the fracture cohort than in the compliance/side effect
cohort (47 vs. 38.8, P < 0.001). Similarly, the scores for each of
the ﬁve domains were signiﬁcantly higher in the fracture cohort.
In the subgroup of index patients who sustained a vertebral frac-
ture a few months before enrolment in the study, the mean total
QUALEFFO score was higher and respectively 55.4 (17) in those
with a lumbar vertebral fracture, 53.1 (15.8) with a thoracic ver-
tebral fracture, 49.4 (15) with a lumbar and thoracic vertebral
fracture. CONCLUSIONS: There is a clear impairment of
quality of life at baseline in the French postmenopausal women
with osteoporosis taking part in the OSSO study, more pro-
nounced in the fracture group. The vertebral fracture worsens
the quality of life.
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OBJECTIVE: Tibia fractures are the most common long bone
fracture and are associated with signiﬁcant morbidity ranging
from infection and amputation to employment problems. Addi-
tionally, general health problems such as stiffness and ongoing
pain are not uncommon. The purpose of this qualitative study
was to examine QoL issues for tibia fracture, develop a concep-
tual model of the QoL impact of fractures and generate a pre-
liminary version of the Fracture-QoL Measure. METHODS:
Data were collected from the literature, orthopedic experts (N =
6) and patients, individually or in focus groups (N = 42), in 4
countries (US, Canada, UK, Germany) by interviews following a
semi-structured interview guide. Transcripts were analyzed for
common themes and the conceptual model and item generation
was based on these themes. Items underwent cognitive debrief-
ing. RESULTS: Tibia fractures have a signiﬁcant negative impact
across multiple aspects of QoL most notably health, relation-
ships and productivity. Contrary to physician beliefs, these
impairments are still evident several years post injury for most
patients. The short term impacts occur in the ﬁrst 4–6 weeks post
injury and include sleep disturbances and work loss. For patients
who do not heal properly or develop infections, the severity of
the impact on QoL midterm (6 weeks–3 months) is greater and
impacts self image and feelings of helplessness. These patients
are at greater risk for long-term consequences which include
divorce and continued mental and physical health issues. The full
conceptual model of the short, mid and long term QoL impacts,
potential determinants and modiﬁers of the relationships along
with the Fracture-QoL Measure will be presented. CONCLU-
SIONS: Improving the ability of orthopedic experts to recognize
the signiﬁcant QoL impacts will facilitate patient access to nec-
essary support services and appropriate treatments. Discussion
of these impacts with patients will help them to be better pre-
pared for a realistic recovery.
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OBJECTIVE: To develop a rating scale to elicit and quantify
patient preferences for different dosing frequencies with bispho-
sphonate therapy in osteoporosis. METHODS: Expert inter-
views generated information for developing descriptions of an
osteoporosis health state along with four different treatment sce-
narios for bisphosphonates: daily, weekly, monthly, and monthly
plus a support programme. A rating scale questionnaire was used
to elicit relative values for the health state and each scenario on
a 0–100 scale. Face and content validity, acceptability and com-
prehension were tested with experts (n = 3) and osteoporosis
patients (n = 22). Telephone administration of the rating scale
was assessed in a pilot study of 50 bisphosphonate users. Con-
struct validity was evaluated in 491 women with or at risk of
osteoporosis who were: naïve to (n = 212), currently taking 
(n = 225) or lapsed (n = 54) bisphosphonate users. RESULTS:
The questionnaire demonstrated good face and content validity,
was acceptable to experts and patients, and suitable for tele-
phone administration taking 5–10 minutes to complete. Con-
struct validity was demonstrated by: (i) Lower valuation for
health state compared with treatment scenarios (median values:
health state = 20, daily = 40, weekly = 70, monthly = 80, and
monthly with support programme = 85); (ii) Non-osteoporotic
women gave lower valuations for health state than women with
osteoporosis (median value = 10, one-way ANOVA, F = 4.80, 
p = 0.009); (iii) Lapsed weekly users gave lower valuations to
weekly scenario (median value = 50) than naïve or current users,
one-way ANOVA, F = 17.68, p < 0.0001; (iv) 94% of lapsed
and 85% of current users who felt they had to take bisphos-
phonates too often, preferred monthly treatment; (v) monthly
dosing with support programme was the most highly valued 
scenario by all patient groups (median value = 85). CON-
CLUSIONS: The preference questionnaire is a valid and accept-
able method for quantifying patient preference for dosing
frequency with bisphosphonate therapy. Overall, bisphospho-
nate treatment scenarios with lower dosing frequencies were
valued more highly.
